Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Portfolio Pulse from Vandana Singh
Promosome, a small biotech firm, has sued Pfizer, BioNTech, and Moderna, accusing them of infringing a patent related to mRNA technology used in their COVID-19 vaccines. This adds to the ongoing patent disputes among biotech companies concerning mRNA COVID-19 vaccine technology.
June 07, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioNTech is being sued by Promosome for alleged patent infringement related to mRNA technology used in its COVID-19 vaccine.
The lawsuit filed by Promosome against BioNTech could potentially lead to financial and legal consequences for the company. This may negatively impact BioNTech's stock price in the short term as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Moderna is being sued by Promosome for alleged patent infringement related to mRNA technology used in its COVID-19 vaccine.
The lawsuit filed by Promosome against Moderna could potentially lead to financial and legal consequences for the company. This may negatively impact Moderna's stock price in the short term as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer is being sued by Promosome for alleged patent infringement related to mRNA technology used in its COVID-19 vaccine.
The lawsuit filed by Promosome against Pfizer could potentially lead to financial and legal consequences for the company. This may negatively impact Pfizer's stock price in the short term as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Alnylam Pharmaceuticals has previously sued Pfizer and Moderna for alleged patent infringement related to lipid nanoparticle technology used in their COVID-19 vaccines.
Alnylam Pharmaceuticals is not directly involved in the current lawsuit filed by Promosome. However, it has previously sued Pfizer and Moderna for alleged patent infringement related to lipid nanoparticle technology used in their COVID-19 vaccines. The ongoing legal disputes may indirectly affect Alnylam's stock price, but the impact is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50